Taofeek K Owonikoko Mukesh Kumar Shu Yang Alice O Kamphorst Rathi N Pillai Rama Akondy Vivek Nautiyal Monica S Chatwal Wendy M Book Anurag Sahu Gabriel L Sica Rafi Ahmed Suresh S Ramalingam
10.1007/s00262-016-1918-2
Cancer Immunol Immunother
2017 Jan;66(1):45-50.
allotransplant antibody cancer immunotherapy pd-1 rejection
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/27771741/
Antibodies, Monoclonal / adverse effects Carcinoma, Squamous Cell / drug therapy Graft Rejection / chemically induced Heart Transplantation / adverse effects Neoplasms / immunology Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / drug therapy
Antibodies, Monoclonal / adverse effects Carcinoma, Squamous Cell / drug therapy Graft Rejection / chemically induced Heart Transplantation / adverse effects Neoplasms / immunology Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / drug therapy Case Reports Allografts Antibodies, Monoclonal / administration & dosage Carcinoma, Squamous Cell / immunology Graft Rejection / immunology Heart Transplantation / methods Humans Immunotherapy / adverse effects Immunotherapy / methods Male Middle Aged Nivolumab Programmed Cell Death 1 Receptor / immunology Skin Neoplasms / immunology Transplantation Immunology Antibodies, Monoclonal PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
PMC5588660
27771741
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
2017